Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus
- PMID: 11145281
- DOI: 10.1080/003655200750056574
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus
Abstract
Background: The application of hyperplasia of the basal cell layer and elongation of the papillae in the squamous epithelium of the distal oesophagus, as histological criteria for the diagnosis of gastro-oesophageal reflux disease (GORD), continues to be controversial. An unanswered question is whether these changes may regress under long-term treatment with proton pump inhibitors (PPI). This fact prompted us to investigate the effect of PPI treatment on the histological changes observed in the lower oesophagus.
Methods: 295 patients with endoscopically confirmed erosive GORD were investigated by endoscopy/biopsy prior to and during the course of a 12-month PPI treatment regimen (8 weeks acute treatment with 30 mg lansoprazole/day followed by long-term treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day). The parameters studied were the frequency of ulcers and erosions and the hyperplasia of the basal cell layer and elongation of the papillae prior to treatment and on day 56 (D56), after 6 months (M6) and after 12 months (M12) of treatment.
Results: In the various treatment groups, the results showed no statistically significant differences. Ulcers and erosions (prior to treatment 21% and 31%, respectively) were detected statistically significantly less frequently under PPI treatment (ulcers, D56: 1%, M6 and M12, 0%; erosions, D56: 2%, M6: 4%, M12, 3%). While high-grade hyperplasia of the basal cell layer and elongation of the papillae was found in 51% of the cases prior to treatment, the corresponding figures were only 3% (D56, M6) and 2% (M12). In contrast, the percentage of cases with normal oesophageal epithelium increased from 8% before treatment to 55% (D56), 66% (M6) and 63% (M12).
Conclusions: Our study shows not only that erosions and ulcers heal under PPI treatment, but also that hyperplasia of the basal cell layer and elongation of papillae in the squamous epithelium of the oesophageal mucosa may normalize, and are thus presumably not 'normal physiological variants'.
Similar articles
-
Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.Aliment Pharmacol Ther. 1997 Feb;11(1):147-56. doi: 10.1046/j.1365-2036.1997.114285000.x. Aliment Pharmacol Ther. 1997. PMID: 9042987 Clinical Trial.
-
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.Eur J Gastroenterol Hepatol. 1998 Sep;10(9):753-8. doi: 10.1097/00042737-199809000-00005. Eur J Gastroenterol Hepatol. 1998. PMID: 9831269 Clinical Trial.
-
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.Dig Liver Dis. 2002 Feb;34(2):95-6. doi: 10.1016/s1590-8658(02)80235-3. Dig Liver Dis. 2002. PMID: 11926565 No abstract available.
-
Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.Drugs. 2005;65(15):2129-35; discussion 2136-7. doi: 10.2165/00003495-200565150-00005. Drugs. 2005. PMID: 16225368 Review.
-
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.Drugs. 1997 Sep;54(3):473-500. doi: 10.2165/00003495-199754030-00010. Drugs. 1997. PMID: 9279507 Review.
Cited by
-
Lansoprazole: an update of its place in the management of acid-related disorders.Drugs. 2001;61(12):1801-33. doi: 10.2165/00003495-200161120-00011. Drugs. 2001. PMID: 11693467 Review.
-
Lansoprazole: in the management of gastroesophageal reflux disease in children.Paediatr Drugs. 2003;5(1):57-61; discussion 62. doi: 10.2165/00128072-200305010-00005. Paediatr Drugs. 2003. PMID: 12513106 Review.
-
Acid challenge to the human esophageal mucosa: effects on epithelial architecture in health and disease.Dig Dis Sci. 2005 Aug;50(8):1488-96. doi: 10.1007/s10620-005-2867-3. Dig Dis Sci. 2005. PMID: 16110841 Clinical Trial.
-
Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.World J Gastroenterol. 2017 May 7;23(17):3174-3183. doi: 10.3748/wjg.v23.i17.3174. World J Gastroenterol. 2017. PMID: 28533674 Free PMC article.
-
Treatment for Barrett's oesophagus.Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD004060. doi: 10.1002/14651858.CD004060.pub2. Cochrane Database Syst Rev. 2010. Retraction in: Cochrane Database Syst Rev. 2021 Mar 4;3:CD004060. doi: 10.1002/14651858.CD004060.pub3. PMID: 20091557 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical